

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Fred Mieras KILLINGER

Serial No.: To be assigned

Art Unit:

Filing Date: Concurrently herewith

Examiner:

For: *Child Resistant Blister Packages
Utilizing Walled Structures
Enclosing Medicament Therein*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references listed on the attached form PTO-1449 as item nos. 23-26 are enclosed
☐ Copies of the references were submitted in parent application Serial No. _____. (37 CFR 1.98(d))
☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

- B. ☐ The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:

- (1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Robert J. Smith
Attorney of Record:
Registration No. 40,820

Date: September 3, 2004
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-9616
Facsimile: (919) 483-7988

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT
ATTORNEY DOCKET NO.
 PR60223USw

SERIAL NO.
 107506879
 To be assigned

APPLICANT
 Fred Mieras KILLINGER

FILING DATE
 Concurrently herewith

GROUP
U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1.	3,809,220	05/07/1974	ARCUDI			
	2.	3,809,221	05/07/1974	COMPERE			
	3.	3,811,564	05/21/1974	BRABER			
	4.	3,835,995	09/17/1974	HAINES			
	5.	3,872,970	03/25/1975	EDISON			
	6.	3,899,080	08/12/1975	BRUNDA			
	7.	3,905,479	09/16/1975	GERNER et al.			
	8.	3,912,081	10/14/1975	HAINES et al.			
	9.	3,912,082	10/14/1975	GERNER et al.			
	10.	3,921,805	11/25/1975	COMPERE			
	11.	3,924,746	12/09/1975	HAINES			
	12.	3,924,747	12/09/1975	GERNER			
	13.	3,941,248	03/02/1976	MOSER et al.			
	14.	4,120,400	10/17/1978	KOTYUK			
	15.	4,125,190	11/14/1978	DAVIE, JR. et al.			
	16.	4,192,422	03/11/1980	KOTYUK			
	17.	4,231,477	11/04/1980	DE FELICE			
	18.	4,485,915	12/04/1984	BERGHAHN			
	19.	5,046,618	09/10/1991	WOOD			
	20.	5,529,188	06/25/1996	COGGSWELL			
	21.	6,047,829	04/11/2000	JOHNSTONE et al.			
	22.	6,523,691	02/25/2003	RAJ et al.			

Continue on page ____

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	23.	WO 96/03329	02/08/1996	WIPO		
	24.	WO 97/39963	10/30/1997	WIPO		
	25.	WO 00/24647	05/04/2000	WIPO		
	26.	WO 01/32532	05/10/2001	WIPO		

Continue on page ____

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

Continue on page ____

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.